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 Protein kinase D (PKD) is a family of serine/threonine kinases that has emerged as a 
novel therapeutic target in multiple diseases; therefore, the development of small molecule 
inhibitors that abrogate PKD’s function has been an area of intense investigation. However, these 
efforts have not yet resulted in a PKD therapeutic that is available for clinical applications. 
Access to structural information can greatly accelerate this drug discovery process and allow 
future initiatives to benefit from structure-based drug design. Therefore, we employed both 
computational and experimental methods to investigate the important characteristics of PKD 
small molecule inhibitors that allow for excellent potency and selectivity. We found that type I 
ATP-competitive PKD inhibitors bind to the hinge region and position a hydrogen bond acceptor 
near the charged side chain of Lys612. An additional moiety (typically a basic amino group) 
capable of developing a critical salt bridge with Glu710 was shown to be important for improved 
affinity. Further analysis from inhibitor selectivity profiles suggested strategic functionalization 
in pocket II could potentially reduce kinase off-target effects. From our experimental 
investigation of CRT0066101 inhibition, we developed a chemical genetic tool kit for evaluating 
PKD function. Mutating the gatekeeper residue, Met659, to phenylalanine or tyrosine 
dramatically sensitized PKD to CRT0066101 inhibition. Conversely, mutating hinge residue, 
G664, to valine or isoleucine conferred resistance. Taken together, our study provides key 
insights into the chemical features associated with PKD inhibition, which will aid in the future 
development of a novel PKD therapeutic.  
STRUCTURAL INSIGHT INTO PROTEIN KINASE D  
SMALL MOLECULE INHIBITION 
 
Evan J. Carder, M.S. 
University of Pittsburgh, 2014
 
 iv 
TABLE OF CONTENTS 
1.0 INTRODUCTION ........................................................................................................ 1 
1.1 PROTEIN KINASE D ......................................................................................... 1 
1.1.1 Protein Structure and Regulation .................................................................. 1 
1.1.2 Signaling in Disease Phenotypes ..................................................................... 3 
1.1.3 Targeted Pharmacological Agents ................................................................. 6 
1.2 KINASE DOMAIN ............................................................................................ 14 
1.2.1 Kinase Structure ............................................................................................ 14 
1.2.2 Small Molecule Kinase Inhibitors ................................................................ 16 
2.0 MOLECULAR FEATURES ASSOCIATED WITH PKD SMALL MOLECULE 
BINDING ..................................................................................................................................... 18 
2.1 INTRODUCTION ............................................................................................. 18 
2.2 MATERIALS ..................................................................................................... 19 
2.2.1 Homology Model Generation ....................................................................... 19 
2.2.2 Docking Parameters ...................................................................................... 20 
2.2.3 Homology Model Validation ......................................................................... 20 
2.2.4 Docking of PKD Small Molecules Inhibitors .............................................. 21 
2.3 RESULTS AND DISCUSSION ........................................................................ 22 
 v 
3.0 BIOCHEMICAL INVESTIGATIONS INTO PKD SMALL MOLECULE 
INHIBITON................................................................................................................................. 33 
3.1 INTRODUCTION ............................................................................................. 33 
3.2 MATERIALS AND METHODS ...................................................................... 35 
3.2.1 Antibodies for immunoblotting, kinase substrates, and inhibitors ........... 35 
3.2.2 Cell stimulation, inhibitor treatment, and cell lysis ................................... 35 
3.2.3 Western blot analysis .................................................................................... 36 
3.3 RESULTS AND DISCUSSION ........................................................................ 37 
4.0 CONCLUSION AND FUTURE DIRECTION ....................................................... 43 
APPENDIX A .............................................................................................................................. 44 
BIBLIOGRAPHY ....................................................................................................................... 46 
 vi 
 LIST OF TABLES 
Table 1. Targeted protein kinase D inhibitors ........................................................................... 7 
 
 vii 
LIST OF FIGURES 
Figure 1. Linear representation of Protein Kinase D ................................................................ 2 
Figure 2. PKD signaling in disease phenotypes .......................................................................... 5 
Figure 3. ATP non-competitive PKD small molecule inhibitors .............................................. 8 
Figure 4. CID755673 Kinome Screen .......................................................................................... 9 
Figure 5. NPKDi and BPKDi chemical structure .................................................................... 10 
Figure 6. NPKDi and BPKDi Kinome Screen .......................................................................... 11 
Figure 7. CRT0066101 and CRT0066051 chemical structure ................................................ 12 
Figure 8. CRT0066101 and CRT0066051 Kinome Screen ...................................................... 12 
Figure 9. Roche139 and SD208 chemical structure ................................................................. 13 
Figure 10.  Kinase domain structure ......................................................................................... 15 
Figure 11. Small molecule kinase inhibitors bound in the active site .................................... 17 
Figure 12. Structural investigation of NPKDi .......................................................................... 22 
Figure 13. Structural investigation of BPKDi .......................................................................... 24 
Figure 14. Structural investigation of CRT0066051 ................................................................ 25 
Figure 15. Structural investigation of CRT0066101 ................................................................ 27 
Figure 16. Structural investigation of Roche 139 ..................................................................... 28 
Figure 17. Structural investigation of Roche SD208 ................................................................ 30 
Figure 18. Trends in putative binding modes of PKD small molecule inhibitors ................. 31 
 viii 
Figure 19. Structural basis for PKD1 active site mutations .................................................... 37 
Figure 20. Cellular PKD1 mutant sensitivity to CRT0066101 treatment .............................. 38 
Figure 21. Cellular PKD1 mutant resistance to CRT0066101 treatment .............................. 40 
Figure 22. PKD kinase homology model validation ................................................................. 44 
Figure 23. Structural investigation into 4-Azaindole kinase inhibitor ................................... 45 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ix 
AWKNOWLEDGEMENTS  
I would like to thank Dr. Qiming Jane Wang for providing me the opportunity to work in 
her laboratory. I am very grateful for the training I received during my time in her group. 
Additionally, I would like to express my appreciation to Dr. Wang lab members for their 
scientific support and friendship.  
 I would also like to sincerely thank Dr. Guillermo Romero for his mentorship and 
scientific support. I thank Dr. Yu Jiang and Dr. Jing Hu for serving on my committee. 
Additionally, I want to thank the Molecular Pharmacology program and the Department of 
Pharmacology and Chemical Biology for financial support and providing me with an opportunity 
to establish a strong foundation in drug discovery.  
 Most of all, I express my deepest gratitude to my friends and family for their 
unconditional love and support during my graduate studies.  
 
 
 
 1 
1.0  INTRODUCTION 
1.1 PROTEIN KINASE D 
1.1.1 Protein Structure and Regulation 
Protein kinase D (PKD) is a family of serine/threonine kinases that were discovered 
during an exciting era when novel kinases were being explored and implicated in a diverse array 
of important signaling events1, 2. Since its discovery, the investigation into PKD’s regulation and 
function has led to a rich source of insight into a broad range of biological processes. The three 
isoforms of PKD identified, PKD1/PKCµ1, 3, PKD24, and PKD3/PKCν5, were initially classified 
as atypical protein kinase Cs (aPKCs); however, they were later grouped into a subfamily of the 
calcium/calmodulin-dependent protein kinase (CAMK) superfamily due to greater sequence 
homology in their catalytic domain. PKD’s general structure consists of three central domains 
bifurcated into the regulatory region and catalytic region (Figure 1). Located near the N-
terminus, PKD’s regulatory region plays a critical role in cellular localization, protein-protein 
interaction, and autoinhibition. Specifically, the tandem cysteine-rich domains (CRD) named 
C1a and C1b bind to second messenger diacyl glycerol (DAG) or DAG analogs phorbol esters 
and facilitate PKD localization at the plasma membrane, mitochondria, and Golgi6-9. The 
pleckstrin homology (PH) domain, which is absent in PKC family members, is commonly 
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associated with inter- and intramolecular interactions and protein localization10. In the context of 
PKD regulation, the CRD and PH domain are responsible for autoinhibition. Mutations at select 
residues or deletion of either the CRD or PH domain leads to an active protein11,12. Positioned 
near the C-terminus, the catalytic region contains the kinase domain, which is responsible for 
PKD’s enzymatic function. Activation of PKD’s kinase domain is due to PKC-mediated 
transphosphorylation of serine residues found within PKD’s activation loop13. Subsequent 
autophosphorylation at the C-terminus results in prolonged enzymatic activity14-17. 
 
 
Figure 1. Linear representation of Protein Kinase D 
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1.1.2 Signaling in Disease Phenotypes 
PKD is integrated in multiple signaling pathways (Figure 2). Acting downstream of G-
protein coupled receptors (GPCR) as well as receptor and non-receptor tyrosine kinases, PKD 
response is associated with a number of different stimuli - GPCR agonists, growth factors, 
oxidative stress, and UV-B radiation18-23. Activation of phospholipase C (PLC) and subsequent 
hydrolysis of phosphatidylinositol 4,5-biphosphate generates second messengers Ins (1,4,5)P3 
and DAG. In turn, DAG binds to PKD’s cysteine-rich domain and induces PKD translocation 
from the cytosol to the cell membrane7, 24, 25. Following PKC-mediated transphosphorylation of 
PKD’s activation loop at Ser744/Ser748, PKD autoinhibition is relieved, thereby, yielding an 
active kinase13, 15, 26. Consequently, PKD rapidly translocates back to the cytosol where it can 
reach various subcellular compartments to propagate key signaling events from the cell surface24.   
 PKD regulates many important signaling pathways that are essential in DNA 
synthesis and cell proliferation. It has been shown that PKD modulates the mitogen-activated 
protein kinase (MAPK) signaling pathway. Aberrant MAPK signaling is associated in the 
development of multiple types of cancer, making it a valid target for anticancer therapeutics27. 
The Ras and Rab interactor 1 (RIN1) protein, in its unphosphorylated form, competes with Raf 
to inhibit the Ras/Raf interaction, thereby reducing downstream MEK/ERK signaling. PKD1 can 
phosphorylate RIN1 at Ser351, resulting in its binding to 14-3-3 proteins and subsequent 
sequestration to the cytosol, thereby, impeding its ability to negatively regulate Ras/Raf28. Thus, 
PKD facilitates sustained stimulation of ERK and consequently c-Fos activity, which can lead to 
increased DNA synthesis and cell proliferation29, 30. Overexpression of PKD resulted in 
prolonged ERK activation in various cancer cells31, providing a potential mechanism through 
which PKD contributes to tumor growth. 
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 PKD affects gene expression by acting on class IIa histone deacetylases (HDAC4, 
5, 7, and 9). HDACs are important epigenetic regulators that control chromatin structure. 
Deacetylation of histones results in enhanced transcriptional repression and reduced gene 
expression. Aberrant class IIa HDACs have been associated in the deregulation of multiple 
signaling events and implicated in adverse phenotypes32. Investigations into cardiovascular 
disease found HDAC5 and HDAC9 negatively regulate cardiac hypertrophy by repressing the 
transcription factor myocyte enhancer factor 2 (MEF2). PKD directly phosphorylates class IIa 
HDACs and facilitates their complex formation with 14-3-3 proteins, leading to HDAC nuclear 
exclusion and sequestration in the cytoplasm, thereby de-repressing MEF2 activity and resulting 
in the expression of target genes33. In neonatal rat ventricular myocytes, PKD-induced 
phosphorylation of HDAC5 led to MEF2-mediated transcription of genes implicated in cardiac 
hypertrophy and heart failure. Additionally, transgenic mice with PKD1-defecient 
cardiomyocytes were resistant to cellular hypertrophy following stimulation by angiotensin II, 
isoprotenerol, or pressure-induced overload.  
 NF-κB is a key transcription factor associated in the expression of multiple genes 
that regulate cell surivival and immune response. In the presence of oxidative stress, PKD is 
recruited to the mitochondria and activated through phosphorylation of its PH domain and 
activation loop by Src-Abl tyrosine kinase and PKCδ, respectively34-36. This leads to PKD-
mediated phosphorylation of inhibitory κ kinase (IKK) and the concomitant degradation of IκB. 
NF-κB released from the inhibitory complex subsequently accumulates in the nucleus and 
induces gene expression. As a result, the generation of manganese-dependent superoxide 
dismutase (MnSOD) aids in cellular detoxification and reduces the risk of cell death. In addition, 
PKD was also shown to support cell survival by influencing the c-Jun N-terminal kinase (JNK) 
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pathway37. Like NF-κB, c-Jun is a transcription factor associated in stress response. PKD is able 
to phosphorylate c-Jun at its N-terminus and suppress JNK-mediated c-Jun activation, which 
inhibits apoptosis38, 39.  
 
Figure 2. PKD signaling in disease phenotypes 
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1.1.3 Targeted Pharmacological Agents 
 Given its role in integrating upstream signaling pathways, PKD is associated in a 
multitude of biological processes. Deregulation of PKD can lead to abnormal activity of multiple 
cellular events, resulting in a broad array of disease phenotypes such as increased DNA 
synthesis, cell proliferation, angiogenesis, hypertrophy, and promote anti-apoptotic and survival 
mechanisms (Figure 2). Therefore, PKD may be a promising therapeutic target. Thus, in an effort 
to further investigate PKD, drug discovery programs has provided a number of PKD 
pharmacological agents.      
 Early investigations into PKD inhibition explored various pan-kinase inhibitors. 
Among those reported, indolocarbazole natural products like staurosporine and its anologs were 
shown to target PKD with low nanomolar concentrations; however, these compounds were also 
recognized as potent PKC inhibitors40. Further studies revealed resveratrol, a stilbenoid natural 
product known for its antioxidant and chemopreventive properties, inhibited PKD as well as 
other protein kinases at micromolar concentrations41. Both classes of inhibitors were highly 
investigated and showed antitumor activity in animal models; although, their poor selectivity 
limited their ability to evaluate PKD in a cellular context. This considerable challenge led to the 
pursuit of PKD-targeted agents (Table 1). 
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Table 1. Targeted protein kinase D inhibitors  
 
 
 CID755673 was the first PKD-specific inhibitor to be reported (Figure 3). 
Possessing a structurally novel benzoxoloazepinolone scaffold, CID755673 inhibited PKD1 at 
approximately 182 nM42. Characterized as an ATP non-competitive inhibitor CID755673 
showed in vitro selectivity over 48 kinases at 10 uM, including several related kinases - PKCα, 
PKCβ, PKCδ, and CaMKIIα (Figure 4). Optimization of CID755673 through structural-activity 
relationship (SAR) resulted in the derivation of its benzoxoloazepinolone core, which led to a 
series of novel analogs. In a hit-to-lead initiative, KB-Nb142-70 represented the lead compound 
that exhibited an improved potency of 28 nM and 2.2 uM in enzymatic and cell-based assays, 
respectively (Figure 3)43. Biological evaluation of CID755673, Kb-NB142-70, and their 
derivatives demonstrated significant reduction in prostate cancer cell proliferation, migration, 
and invasion42, 43. Small molecule inhibition phenocopied siRNA-induced PKD knockdown; 
therefore, the study showed that pharmacological perturbation of PKD could suppress cancer-
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associated biological responses. However, Kb-NB142-70’s pharmacokinetic profile indicated 
poor metabolic stability. Undergoing phase I and II metabolism, rapid oxidation and 
glucuronidation of Kb-NB142-70 resulted in a plasma half-life of 6 minutes44. In order to 
abrogate these enzymatic modifications and improve its pharmacokinetic profile, the derivation 
of Kb-NB142-70 led to KMG-NB4-23, which contained an electron deficient 
methoxypyrimidine (Figure 3). KMG-Nb4-23 exhibited a relatively similar IC50 of 124 nM; 
however, due to poor aqueous solubility (less than 0.4 mg/mL), KMG-NB4-23 was not evaluated 
in vivo45. Although CID755673 and Kb-NB142-70 are not being pursued as therapeutic agents, 
they remain valuable compounds for probing PKD-regulated signaling events and biological 
activities in vitro and in cells.  
 
 
Figure 3. ATP non-competitive PKD small molecule inhibitors 
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Figure 4. CID755673 Kinome Screen 
 
 In addition to CID755673 and its analogs, Novartis developed a series of ATP-
competitive PKD inhibitors following an extensive HTS campaign and subsequent optimization 
through SAR analysis. Their lead naphthyridinylpyridinamine PKD inhibitor (NPKDi, Figure 5) 
targeted PKD at subnanomolar concentrations, having an impressive IC50 of 1 nM46. 
Investigating PKD associated-HDAC5 nuclear export in cardiomyocytes, NPKDi was able to 
abrogate PKD autophosphorylation and reduced PMA-stimulated phosphorylation of HDAC5 in 
isolated peripheral blood mononuclear cells (PBMC) from NPKDi-treated Dahl salt-sensitive 
(DSS) rats46. However, NPKDi showed poor selectivity. Out of a panel of 200 kinases, NPKDi 
potently targeted CaMKIIδ, GSKα/β, p38δ, MARK1/2 kinase at 1 μM (Figure 6)47.  This 
limitation made it challenging to assess NPKDi’s pharmacological inhibition of PKD in cardiac 
hypotrophy. Thus, an effort to find a more selective PKD inhibitor was pursued. The 
development of an ATP-competitive amidobipyridyl PKD inhibitor was reported to blunt in vitro 
CID755673 
 10 
PKD1 activation at 1 nM (BPKDi, Figure 5). BPKDi also reduced HDAC phosphorylation in 
cell-based assays and provided improved selectivity over NPKDi off-target kinases at 1 uM 
(Figure 6)47. However, BPKDi failed to reduce pressure-overload-induced cardiac hypertrophy in 
both DSS and aortic-banded rats. This contradicts previous results, which revealed genetic 
knockout of PKD1 relieved pressure-overload-induced cardiac hypertrophy48. This may suggest 
pharmacological inhibition of PKD1 activity may not confer the same phenotypic response as 
PKD1 knockout. In general, discrepancies between genetic and pharmacological-based studies 
have been documented; although, in this case, further investigation is required to probe this 
variance49. Nonetheless, Novartis reported the first in vivo PKD targeted inhibitor that potently 
inhibited PKD activation and reduced HDAC5 nuclear export. Furthermore, in their animal 
study, NPKDi was administered orally up to 50 mg/kg/day with no apparent toxicity. However, 
due to poor solubility and negligible bioavailability, BPKDi required subcutaneous 
administration at up to 5 mg/kg/day. In order for these inhibitors to provide clinical value, 
modifications to improve their PK/PD and ADME profiles will be necessary.  
 
Figure 5. NPKDi and BPKDi chemical structure 
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Figure 6. NPKDi and BPKDi Kinome Screen 
 
 Cancer Research Technology drug discovery program was next to report 
CRT0066051 and CRT0066101, an aminopyridine phenyl- and an aminopyrimidine phenol-
based ATP-competitive PKD inhibitor, respectively (Figure 7). The two CRT independent series 
targeted PKD1 at subnanomolar concentrations (0.4 and 0.7 nM, respectively) and portrayed 
submicromolar activity in cell base assays. Moreover, in a limited kinome screen of 36 kinases, 
CRT0066051 was shown to be very selective for PKD compared to CRT006610, which has 
limited off target effects, inhibiting CDK2, IKKα, PRK2, and Rsk1 at 1 uM (Figure 8). 
Biological evaluation of human umbilical vein endothelial cells (HUVEC) showed treatment 
with CRT0066051 reduced VEGF-induced endothelial cell proliferation, migration, and 
tubulogenesis, suggesting a role of PKD in angiogenesis50. This study revealed CRT0066051 
efficacy in cells; however, its ADMET properties were not determined and therefore its in vivo 
profile is currently unknown. Investigating PKD in a pancreatic cancer mouse xenograft model, 
NPKDi BPKDi 
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CRT0066101 significantly reduced tumor progression by abrogating PKD activation, stunting 
cell proliferation, and inducing apoptosis in vivo51. Importantly, CRT0066101 showed excellent 
oral bioavailability and no toxicity was observed at an oral dosage of 80 mg/kg/day51. Currently, 
CRT0066101 is the most promising PKD small molecule inhibitor; however, further 
investigations will be required before CRT0066101 can advance toward a clinical setting.  
 
 
Figure 7. CRT0066101 and CRT0066051 chemical structure 
 
 
Figure 8. CRT0066101 and CRT0066051 Kinome Screen 
CRT0066101 CRT0066051 
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In addition to the development of inhibitors that selectively block PKD activity, several 
dual PKD inhibitors were identified. These new PKD inhibitory scaffolds are the result of small-
scale kinase-targeted library screens. Among them, Roche 139, a 4-azaindole scaffold from 
Hoffmann-La Roche, Inc. was found to potently inhibit PKD at 16.8 nM (Figure 9.)52. Although 
it is selective against PKC and CaMK family kinases, investigations into known 4-azaindole 
kinase inhibitors revealed Roche 139 effectively targets p38α MAP kinase at low nanomolar 
concentrations. Therefore, future drug discovery studies may provide Roche 139 an opportunity 
as a multi-targeted protein kinase inhibitor. The most recent PKD inhibitor, SD208 contains a 
pteridine core and targets PKD at low submicromolar concentrations (Figure 9). Originally 
employed as a potent TGFβ receptor I inhibitor, recent studies indicated SD208 potently inhibits 
PKD at similar concentrations, therefore SD208 can be employed as a dual PKD/TGFβRI 
inhibitor.  Moreover, in a prostate cancer tumor xenograft model mice treated with SD208 
showed a marked decrease in tumor growth. Thus, SD-208 represents a novel PKD inhibitory 
chemotype with in vivo efficacy that could potentially be further developed into a cancer 
therapeutic. 
  
Figure 9. Roche139 and SD208 chemical structure 
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1.2 KINASE DOMAIN 
1.2.1 Kinase Structure 
Protein kinases contain a catalytic domain that is composed of a conserved globular 
structure featuring two lobes, N- and C-terminal lobe (Figure 10A). The N-terminal lobe is 
relatively smaller in size and primarily consists of a β-sheet and a single α-helix, which is known 
as the αC-helix. The C-terminal lobe is considerably larger and mostly alpha helical. A peptide 
chain called the hinge connects this bi-lobed system and establishes an intervening cleft 
recognized as the catalytic core. ATP binds within this region and forms critical hydrogen bonds 
between the nitrogen atoms of the adenine ring and the peptide backbone of the hinge (Figure 
10B). This aids in positioning the purine moiety in a favorable environment, forming van der 
Waals interactions with nearby nonpolar aliphatic residues. Additional interactions critical for 
ATP binding rely on several conserved residues distinguished in the kinase active conformation. 
The activation of protein kinases and the subsequent binding of ATP is regulated by the 
activation loop, a short segment located in the C-terminal lobe near the ATP binding site. The 
activation loop begins with a conserved DFG motif, which plays an important role in defining 
the kinase’s active conformation. In an activated state, the aspartate of the DFG motif chelates a 
magnesium ion, thereby stabilizing the alpha and gamma phosphate groups of ATP. Additional 
residues in the N-terminal lobe further support the phosphate groups and assist in optimally 
positioning ATP for catalysis. A conserved glutamate found in the αC-helix coordinates with a 
lysine in the β3 strand, which enables lysine to associate with the α- and β-phosphate groups of 
ATP. Further interactions occur between the active kinase domain and ATP; however, loss of the 
conserved aspartate from DFG or lysine confers a functionally incompetent kinase53, 54. 
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 A. 
 
 B. 
 
Figure 10.  Kinase domain structure 
A. Bi-lobed architecture. B. ATP bound in a kinase active site. (PDB:1O6L)   
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1.2.2 Small Molecule Kinase Inhibitors  
The association of protein kinases in various diseases resulted in the pursuit of kinase 
inhibitors. To date, most kinase inhibitors compete with ATP binding, thereby, abrogating the 
kinase’s catalytic function55. ATP-competitive inhibitors exhibit various heterocyclic scaffolds 
that can mimic the hydrogen bond formation of the adenine ring of ATP with residues at the 
hinge region. Type I inhibitors represents the majority of ATP-competitive inhibitors and target 
the kinase in its active conformation56. Therefore, type I inhibitors traditionally target regions 
near the ATP binding site and exploit distinct kinase properties, which contribute to their 
potency and selectivity57. A common place for exploitation is a solvent exposed hydrophobic 
pocket (pocket I) located at the hinge region near the entrance of the active site (Figure 11). An 
internal hydrophobic pocket (pocket II), which is partitioned by the gatekeeper residue, is also an 
area of exploitation56. In contrast, type II inhibitors recognize the inactive conformation. Due to 
the adopted DFG-out conformation associated in the kinases inactive state, type II inhibitors 
have additional exposure to an allosteric site neighboring the ATP binding site (Figure 11). Due 
to greater conformational heterogeneity of inactive protein kinases, it is suggested that type II 
inhibitors have the capability for improved kinase selectivity. However, allosteric inhibitors, 
which bind outside the ATP-binding site tend to exhibit the greatest kinase selectivity since they 
likely target regions unique to the kinase.  
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 A. 
 
 B. 
 
Figure 11. Small molecule kinase inhibitors bound in the active site 
A. Type I ATP-competitive inhibitor B. Type II ATP-competitive inhibitor 
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DFG  
motif 
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2.0  MOLECULAR FEATURES ASSOCIATED WITH PKD SMALL MOLECULE 
BINDING 
2.1 INTRODUCTION 
The pursuit of PKD small molecule inhibitors has provided a diverse set of inhibitory 
scaffolds that show promising pharmacological and biological properties. However, the key 
chemical features associated with PKD inhibition are unknown. Access to structural information 
can greatly accelerate PKD drug discovery efforts and allow future initiatives to benefit from 
structure-based drug design. In the case of PKD, there is currently no crystal structure available, 
which makes rational design of potent and selective PKD inhibitors a considerable challenge. 
Therefore, through careful analysis of the chemical features of known PKD inhibitors and their 
respective SAR, we developed a PKD homology model to determine putative binding modes of 
PKD inhibitors within the kinase active site. This analysis alluded to structural determinants 
important for PKD inhibition and provided valuable structural details, which will aid in the 
future design of more potent and selective PKD inhibitors. 
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2.2 MATERIALS 
2.2.1 Homology Model Generation 
Currently, there is no crystallographic data for PKD; therefore, to investigate the 
structural features necessary for PKD small molecule inhibition, we developed a PKD homology 
model using the I-TASSER server. Submitting the primary amino acid sequence of PKD’s kinase 
domain (residues 587 to 835), the I-TASSER performed a position-specific iterated BLAST 
(PSI-BLAST) to identify evolutionarily similar homologs. Aligning these proximal relatives 
assisted in the prediction of secondary structural motifs.  The primary amino acid sequence in 
conjunction with the predicted secondary structures were employed to retrieve template proteins 
with similar folds from the Protein Data Bank (PDB) library using LOMETS threading, a locally 
installed meta-threading approach. The subsequent protein structures were selected as templates:  
1QL6 (rabbit, phosphorylase kinase), 2BDW (c. elegans, calcium/calmodulin kinase II), 3MFR 
(human, calcium/calmodulin activated serine-threonine kinase), 2JAM (human, 
calcium/calmodulin-dependent protein kinase I G), and 2Y7J (human, phosphorylase kinase 
gamma 2). Following this threading procedure, the I-Tasser program split the templates into 
fragments based on template-sequence alignment and reassembled the fragments to create full 
length models. These resulting models were refined to their lowest energy state utilizing REMO 
and FG-MD programs, which optimized the C alpha backbone torsional angles, bond lengths, 
and side chain rotatmer orientations to generate fully refined, high quality predictive models of 
PKD’s three-dimensional structure. 
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2.2.2 Docking Parameters 
 To perform docking calculations on PKD small molecule inhibitors, we employed the 
Surflex-Dock GeomX (SFXC) program using Sybyl-x 2.1 software. For each homology model 
of PKD’s kinase domain all hydrogen atoms were present. The docking site, known as the 
Surflex-Dock Protomol, is the volumetric space in which inhibitors are evaluated. The protomol 
was configured to specifically target the ATP binding pocket and constructed using the following 
residues: Ala610, Lys612, Met659, Glu660, Lys661, Leu662, His663, Glu710, Leu713, Cys726.  
Additionally, the protomol was restricted to a threshold of 0.6 and a bloat of 3.0, which resulted 
in a sufficient pocket to conduct docking calculations. The SFXC program was instructed to 
evaluate an additional twenty starting conformations per molecule. Moreover, we introduced 
flexibility to protein atoms whose distance was less than 4 Å from the docked ligand. Ligands 
were prepared according to the Docking_Conformation protocol, which generate a SLN file of 
multiple samples of tautomers, stereoisomers, and conformers. The designed protomol as well as 
the ligand’s SLN file was entered into SFXC program for docking analysis. 
2.2.3 Homology Model Validation 
Despite receiving high quality models from the I-TASSER server, there was a level of 
considerable uncertainty associated with the resulting predictive structures. Therefore, we 
assessed and validated models based on experimental findings. Docking calculations of literature 
reported PKD inhibitor NPKDi was performed using the Surflex-Dock GeomX (SFXC) program 
under the previously described parameters. The binding modes as well as key amino acid 
interactions were compared to that presented in literature. Specifically, models were evaluated 
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according to their ability to produce high docking scores, resulting from interactions with hinge 
residue Leu662, conserved catalytic residue Lys612, and sugar pocket residue Glu710 (Figure 
22).  
2.2.4 Docking of PKD Small Molecules Inhibitors 
Employing our PKD homology model, we rationally determined putative binding modes 
for PKD small molecule inhibitors. Docking calculations were performed as previously 
described. Binding modes were initially evaluated according to their compliance with the 
characteristics appropriate for type I ATP-competitive inhibitors. The remaining binding modes 
were assessed according to their agreement with their respective experimentally derived 
structural activity relationship analysis. The most rational putative binding mode for each 
inhibitor evaluated was selected. 
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2.3 RESULTS AND DISCUSSION 
 A. 
 
B. 
 
Figure 12. Structural investigation of NPKDi 
A. SAR evaluation B. Molecular modeling 
 
Novartis’ investigation of the 2,6-naphthyridine scaffold revealed distinct chemical 
features associated with PKD inhibition. Initial functionalization of the naphthyridine core 
(black) led to the addition of 1-piperazine (R1= H, R2= piperazine: green), which resulted in 
more than a 200-fold increase in PKD selectivity over PKCα (Figure 12A). In addition, 
introduction of cyclohexylamine (R1=cyclohexylamine: red, R2= piperazine: green) at the 2-
pyridine position afforded subnanomolar activity (0.6 nM) against PKD and remarkable 
NPKDi 
Chemotype Lead Compound 
 
SAR 
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selectivity over PKC isoforms PKCα and PKCδ. Molecular modeling of NPKDi suggested a 
putative binding mode within the active site and provided rationale for PKD inhibition                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
(Figure 12B). The nitrogens from the cyclohexylamine (red) and pyridine (blue) of NPKDi form 
two hydrogen bonds with the peptide backbone of Leu662 at the hinge region. The cyclohexyl 
group is positioned in pocket I and the piperazine was found in the ribose sugar region where it 
can form a salt bridge with Glu710. The 6-nitrogen (yellow) from the naphthyridine core 
generated a hydrogen bond with the positively charged side chain of the catalytic residue 
Lys612. SAR analysis indicates that other nonpolar alkylamine substituents in the R1 position 
were well tolerated. Additionally, it confirmed the basic nitrogen in the piperazine ring (green) as 
well as the nitrogen in the naphthyridine core (yellow) is necessary for inhibition. Loss of either 
one of these chemical components resulted in decreased potency. Thus, these findings offer great 
insight into PKD’s active site and suggest important chemical characteristics for PKD inhibition. 
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 A. 
 
B.  
 
Figure 13. Structural investigation of BPKDi 
A. SAR evaluation B. Molecular modeling 
 
Following the structural guide established from the development of NPKDi, the design of 
an amidobipyridyl PKD inhibitor maintained similar chemical features. BPKDi retained the 
cyclohexylamine (red) and piperazine (green) functionality (Figure 13A). Since the 
amidobipyridyl chemotype (black) relinquished a fused ring system, R3 substituents with 
hydrogen bond capabilities with Lys612 were investigated. Introduction of a primary amide 
group (yellow) showed low nanomolar potency (1 nM). Pyrazole derivatives were also found to 
be equally as potent. Moreover, BPKDi has a marked improvement in its selectivity profile 
(Figure 6). Since the chemical structures of BPKDi and NPKDi are similar and their PKD 
Chemotype Lead Compound 
 
SAR 
BPKDi 
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inhibitory activities are comparable, this differential in selectivity is rather significant. As shown 
in Figure 13B, molecular modeling results suggested that the primary amide forms additional 
interactions with residues positioned in pocket II, which we believe may be conducive for its 
improved PKD selectivity. Further investigation into selectivity is required. These findings 
reaffirm the chemical characteristics associated with NPKDi inhibition and suggested possible 
trends in targeting PKD.  
A. 
 
B.  
 
Figure 14. Structural investigation of CRT0066051 
A. SAR evaluation B. Molecular modeling 
 
In contrast to BPKDi, CRT0066051 has an amino pyridine core with 6-ethoxy-2-naphthyl 
and N,N-dimethylaminoethylbenzamido substituents. Studies into this compound revealed the 
Chemotype Lead Compound 
 
SAR 
CRT0066051 
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value of the 2-aminopyridine, which parallels the functionality of adenine of ATP. Removal of 
the exocyclic amino group (blue) or changing its position from C-2 to C-6 resulted in decreased 
potency (Figure 14A). Additionally, alkylation of exocyclic amine was shown to be detrimental 
to PKD activity. As illustrated in Figure 14B, molecular modeling suggested this functionality 
forms classical hydrogen bonds with the peptide backbone of residues at the hinge region, 
thereby positioning the inhibitor within the ATP binding site. Therefore, alkyl functionalization 
of the exocylic amine would potentially disrupt hydrogen-bonding interactions at the hinge or 
clash with the gatekeeper residue, thereby interfering with inhibitor binding.  The N,N-
dimethylaminoethylacetamide side chain was also found to be important for PKD inhibition. 
Upon inspection of R1 substituents, two carbon atoms are preferred for the amino alkyl chain 
(green) and loss of the terminal amino group resulted in an inactive compound, which makes this 
functionality critical for inhibition.  Molecular modeling suggested the charged terminal amino 
group forms a salt bridge with Glu710, likening both Novartis’ compounds. Additionally, the 
oxygen associated with the 6-ethoxy-2-naphthyl substituent (yellow) is positioned to form a 
hydrogen bond with Lys612. The 6-ethoxy group may extend into Pocket II, which could 
contribute to CRT0066051’s excellent selectivity (Figure 8). Also, SAR analysis investigating 
R2 substitutions revealed functionality with hydrogen bond capabilities was tolerated and 
important for reduced enzymatic activity. Evaluation of CRT0066051 illustrated conserved 
interactions between PKD inhibitors and PKD’s active site, suggesting possible trends in PKD 
inhibition. 
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A.  
 
B.  
 
Figure 15. Structural investigation of CRT0066101 
A. SAR evaluation B. Molecular modeling 
 
CRT0066101 represents a novel chemotype, exhibiting an aminopyrimidine scaffold. 
Exploration of the R1 amino alkyl substituents found that the aminoethyl (green) was preferred 
over longer alkyl chains (Figure 15A). Small substituents alpha to the terminal amine was 
tolerated and helped improve potency as well as cell permeability. Additionally, like 
CRT0066051, the terminal amine was determined essential for PKD inhibition and our model 
showed it forms favorable interactions with Glu710. Investigations into the phenyl ring 
concluded the phenolic hydroxyl (red) is essential for inhibition. Additionally, evaluation of the 
pyrimidine concluded the nitrogen (blue) at the 1-position was also required (Figure 15B). 
Chemotype Lead Compound 
 
SAR 
CRT0066101 
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Molecular modeling revealed the oxygen (red) from the phenolic hydroxyl and the 1-nitrogen 
(blue) from the pyrimidine establish a hydrogen bond clamp with the peptide backbone at the 
hinge. Therefore, this proposed orientation of the pyrimidine would suggest the tolerance of C-5 
substituents positioned into pocket I. Indeed SAR analysis confirmed that various derivations 
(e.g., methyl, phenyl, 4-pyrazole) at C-5 were well tolerated. Further exploration into the 
phenolic ring revealed that electron withdrawing R2 substituents para to the phenolic hydroxyl 
group was also tolerated. However, substitution at this position had marginal affect on potency, 
which implied no additional interactions are formed. In general, CRT0066101 is comparably 
more consolidated within PKD’s active site; however, it distinctly exploits common features 
associated with PKD inhibition.   
A. 
 
B.  
 
Figure 16. Structural investigation of Roche 139 
A. Distinct chemical features B. Molecular modeling 
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Although early in development, we applied our understanding of PKD inhibition and 
rationalized putative binding modes for novel PKD inhibitors Roche 139 and SD208, suggesting 
potentially important interactions associated with their binding. Roche 139 has a 1H-pyrrolo[3,2-
b]pyridine scaffold with 4-fluorphenyl and 2-alkylaminopyridyl substituents (Figure 16A). 
Investigation into this scaffold revealed a known 4-azaindole kinase inhibitor, 9 (as labeled in 
paper), which portrays similar chemical characteristics to Roche139 (Figure 23A). 9 is well 
characterized and has been co-crystalized with p38 MAP kinase. Applying our PKD analysis we 
deduced rational features associated with Roche 139 inhibition, which was supported by the co-
crystal structure of 9. As illustrated in Figure 16B, both nitrogens from the amino pyridine (red 
and blue) as well the oxygen (red) from the propan-1-ol side chain formed optimal hydrogen 
bonds with the peptide backbone of residues at the hinge region. Additionally, the 4-
fluorophenyl substituent (purple) extends into pocket II and the nitrogen from the fused pyridine 
(yellow) formed a potentially critical hydrogen bond with the charged sided chain of Lys612. 
Both of these inhibitory characteristics were also illustrated in the binding of 9 in p38 MAP 
kinase (Figure 23B). Roche139 contains similar chemical features with other PKD inhibitors; 
however, it wasn’t shown to exploit a valuable interaction with Glu710. Future efforts should 
consider additional functionalization, which may improve Roche139’s potency and selectivity. 
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A.  
 
B.  
 
Figure 17. Structural investigation of SD208 
A. Distinct chemical features B. Molecular modeling 
 
In contrast to Roche 139, SD208 contains a pteridine core with 4-aminopyridyl and 5-
chloro-2-fluorophenyl substituents (Figure 17A). Molecular modeling of SD208 revealed 
hydrogen-bonding interactions between the amino acids at the hinge region and its nitrogens in 
the pteridine core (red and blue).  Additionally, SD208 may also form a potentially critical 
hydrogen bond with the nitrogen from the 4-aminopyridine (yellow) and the charged side chain 
of Lys612 (Figure 17B). The limited SAR analysis conducted for SD208 supported the notion 
that the nitrogen from the 4-aminopyridine acts as a valuable hydrogen bond acceptor.  Ablation 
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of this bond revealed a marked decrease in PKD1 inhibition. Interpreting this putative binding 
mode, it’s possible that additional medicinal chemistry efforts could functionalize select 
positions of SD208 to take advantage of Glu710 and interactions within pocket II. This may 
enhance potency and improve SD208’s selectivity for PKD. 
 
Figure 18. Trends in putative binding modes of PKD small molecule inhibitors 
 
Molecular modeling and SAR analysis of PKD small molecule inhibitors highlighted key 
chemical elements and unique structural features required for PKD inhibition (Figure 18). 
Common among ATP-competitive inhibitors, a core heterocyclic scaffold was necessary to form 
hydrogen bonds at the hinge region in a similar fashion to adenine of ATP. An orthogonal 
substituent or linker that traverses the active site positioned an additional hydrogen bond 
acceptor to interact with the charged side chain of Lys612. This substituent or linker could be 
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relatively flexible (e.g., BPKDi) or rigid (e.g., the fused aromatic ring system of NPKDi or 
CRT0066051); however, it carefully accommodated PKD’s considerably large gatekeeper 
residue, Met659. Additionally, a functional moiety (typically a basic amino group) capable of 
developing a critical salt bridge with Glu710 was shown to be important for added affinity. Thus, 
this interaction can be generated by appropriately functionalizing the core heterocyclic scaffold 
(e.g., CRT0066101 and CRT0066051) or the traversing substituent (e.g., NPKDi and BPKDi). 
Exploiting the two hydrophobic pockets may improve improve potency and selectivity. For 
PKD, pocket I is likely solvent exposed and can tolerate both polar and non-polar groups. Due to 
the size of the sterically cumbersome gatekeeper residue, introducing favorable interactions 
within pocket II may be challenging. However, analyzing the selectivity profile of BPKDi and 
CRT0066051, we believe further functionalization in pocket II may dramatically reduce kinase 
off-target effects. Based on SAR analysis, it appeared small substituents are well tolerated. 
Further exploitation of pocket II could provide new information and may result in more selective 
PKD inhibitors. Future drug discovery efforts should look to take advantage of all the required 
chemical features to develop a more potent and selective PKD inhibitor. 
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3.0  BIOCHEMICAL INVESTIGATIONS INTO PKD SMALL MOLECULE 
INHIBITON 
3.1 INTRODUCTION 
Most kinase inhibitors target the kinase active site and compete with ATP binding, 
thereby, abrogating the kinase’s catalytic function55. These ATP-competitive inhibitors contain 
various heterocyclic scaffolds that can mimic the hydrogen bond formation of the adenine ring of 
ATP with residues at the hinge region56. Type I inhibitors represents the majority of ATP-
competitive inhibitors and target the kinase in its active conformation. Therefore, type I 
inhibitors traditionally target regions near the ATP binding site and exploit distinct kinase 
properties, contributing to their potency and selectivity57. A common place for exploitation is a 
solvent exposed hydrophobic pocket (pocket I) located at the hinge region near the entrance of 
the active site. This area can contain various amino acids that are uniquely positioned, offering 
heterogeneity among protein kinases. Kinase inhibitors that exploit this region position both 
polar and non-polar functional groups in pocket I56.  Also, another targeted region is hydrophobic 
pocket II. Pocket II neighbors the ATP binding site and is partitioned by the gatekeeper residue, 
which dictates the relative cavity size of pocket II and regulates inhibitor accessibility58. Protein 
kinases have varying gatekeeper residues. Many tyrosine kinases contain a threonine amino acid 
at this position, which is a relatively small gatekeeper residue with hydrogen bond capabilities, 
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making the exploitation of pocket II advantageous59. Therefore, it is common for tyrosine kinase 
inhibitors to have functional groups positioned in this region. On the other hand, most 
serine/threonine kinases, like PKD, contain a larger methionine residue, thereby, making it 
considerably more challenging to access pocket II. Drug discovery efforts look to take advantage 
of these kinase-specific features, thus, having a structural understanding can provide the basis for 
rational drug design and improve kinase/inhibitor interactions. 
 It has been well reported that type I ATP-competitive inhibitors are affected by 
mutations in the ATP binding region. In a recent study investigating inhibitor resistance in 
protein kinases, investigators found point mutations at two specific positions within the ATP 
active site that reduced inhibitor sensitivity60. Specifically, select mutations of the gatekeeper 
residue or a downstream glycine residue found on the hinge loop near pocket I disrupted 
inhibitor binding. Since there is currently no experimental data suggesting the binding modes of 
PKD small molecule inhibitors, we postulate that mutations at these two regions to larger, more 
sterically cumbersome amino acids would selectively interfere with inhibitor exploitation. PKD 
small molecule inhibitors offer a variety of diverse inhibitory scaffolds, so it is possible that 
these mutations could have varying effects. Therefore, we introduced individual amino acid 
substitutions at the gatekeeper and into the hinge region of PKD and evaluated inhibitor 
sensitivity.     
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3.2 MATERIALS AND METHODS 
3.2.1 Antibodies for immunoblotting, kinase substrates, and inhibitors 
 The following antibodies were used for immunoblotting: rabbit anti-phosphoSer916 
PKD1 (working dilution 1:2000; Millipore), mouse anti-flag (working dilution 1:2000), mouse 
anti-tubulin (working dilution 1:2500; Santa Cruz Biotechnology ). CRT0066101 was a kind gift 
from Cancer Research Technology. 
3.2.2 Cell stimulation, inhibitor treatment, and cell lysis  
HEK 293 cells were transfected with the plasmid containing the indicated Flag-PKD1-
WT or Flag-PKD1-mutant using Lipofectamine 200 transfection reagent according to the 
manufacturer’s suggestions. The cells transfected with indicated Flag-PKD1-WT and Flag-
PKD1-mutant were deprived of serum for 18 hr. PKD inhibitor, CRT0066101, or the equivalent 
volume of DMSO as a control, was added to the cell culture medium 90 minutes prior to 
stimulation. The cells were then stimulated with 10 nM PMA for 20 minutes. Finally, treated 
HEK 293 cells were lysed in 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1.5 mM MgCl2, 10% 
glycerol, 1% Triton X-100, 5 mM EDTA, 20 μM Leupeptin, 1 mM phenylmethylsulfonyl 
fluoride (PMSF), 1 mM NaVO3, and 10 mM NaF, and incubated on ice. Cell lysates went 
through three consecutive freeze-thaw cycles and centrifuged for 10 minutes at 13,000 rpm at 4 
°C in an Eppendorph microcentrifuge. Protein amounts were measured with BCA Concentration 
Assay kit (Pierce) as specified by the manufacturer, and equivalent amounts of total protein of 
each cell lysate were analyzed by western blot.  
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3.2.3 Western blot analysis  
Western blot analysis was carried out to analyze expression of various proteins. Equal 
amounts of protein were subjected to SDS-PAGE and subsequent electrotransfer to nitrocellulose 
membranes. Membranes were pre-blocked in 5% nonfat milk in Tris-buffered saline with 0.01% 
Tween-20 (TBS-T) and then incubated with primary antibodies in 5% BSA overnight at 4°C. 
Primary antibodies against pS916-PKD1, flag, and tubulin were used. Membranes were washed 
in TBS-T and then incubated for 1 h at room temperature with secondary anti-rabbit or anti-
mouse antibodies conjugated to horseradish peroxidase (HRP, Bio-Rad). Detection of specific 
protein bands was facilitated by the enhanced chemiluminescence (ECL) Western blotting 
detection system (Amersham Biosciences). Densitometry analysis was performed using Image 
Lab from ChemiDoc MP System (Bio-Rad). 
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3.3 RESULTS AND DISCUSSION 
 A. 
 
 
B. 
 
Figure 19. Structural basis for PKD1 active site mutations 
 
A. Cartoon representation of the active site of a PKD1 kinase homology model bound to 
CRT0066101. Residues selected as candidates for mutation in this study are illustrated by 
spheres (red: gatekeeper residue, Met659; green: pocket I residue, Gly664). Molecular 
models were rendered with pymol (www.pymol.org). B. Sequence alignment of the hinge 
region of PKD kinase domain. The mutations highlighted are the gatekeeper residue 
M659 (red) and pocket I residue Gly664 (green). 
CRT0066101 
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Experimental evidence describing PKD small molecule inhibitor positioning within 
PKD’s kinase domain is unknown. Therefore, to explore inhibitor binding and to investigate 
regions of kinase exploitation within PKD’s active site, we independently generated select 
mutations and evaluated its effects on kinase sensitivity. Specifically, we conducted site-directed 
mutagenesis of PKD’s gatekeeper residue, Met659, and hinge residue, Gly664, positioned at 
pocket I (Figure. 19). We posited that mutating these residues to larger, more sterically 
cumbersome amino acids would obstruct inhibitor binding and thereby, desensitize PKD from 
pharmacological inhibition.   
 
 
 
 
Figure 20. Cellular PKD1 mutant sensitivity to CRT0066101 treatment 
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HEK 293 cells transiently expressing Flag-PKD1-WT, Flag-PKD1-M659Y, and Flag-
PKD1-M659Y were serum starved for 18 hours. Following, cells were treated with the 
indicated concentration of CRT0066101 for 90 minutes and subsequently induced with 
10 nM of PMA. Cells were collected and lysed. Total cell lysate was analyzed by 
immunoblotting with anti-pSer916 PKD1-specific antibody for kinase activity, anti-flag 
antibody for transfection efficiency, and anti-tubulin for loading control. Densitometric 
quantification was performed using Image Lab (Bio-Rad) and the activity was 
normalized against the transfection efficiency and with the loading control.  
 
To probe pocket II occupancy, we constructed Flag-PKD1-M659F and -M659Y mutants, 
which would reduce pocket II cavity size and limit the window for inhibitor exploitation. 
Expressing these mutants in HEK 293 cells in the presence of increasing concentrations of potent 
PKD small molecule inhibitor, CRT0066101, we anticipated reduced inhibitor activity compared 
to the treatment of Flag-PKD1-WT. Following western blot analysis of PKD1’s activity 
according to PMA-induced PKD autophosphorylation at Ser916, we were surprised to observe 
an increase in CRT0066101 sensitivity. The cellular EC50 for Flag-PKD1-WT was determined to 
be 10.84 μM; however, for mutants Flag-PKD1-M659F and –M659Y their cellular EC50 was 
markedly reduced to 0.527 and 0.629 μM, respectively (Figure 20). These results suggest 
CRT0066101 does not occupy pocket II. More interestingly, M659F and M659Y amino acid 
substitutions enhanced inhibitor binding, which indicate these residues introduced a new 
chemical interaction and assisted with stabilizing CRT0066101 in PKD’s active site. Both 
phenylalanine and tyrosine have aromatic amino acid side chains. It is possible that these 
residues allow for pi-pi stacking with an aromatic ring of CRT0066101. Based off of the rational 
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putative binding mode of CRT0066101 within our PKD kinase homology model, it is plausible 
that this non-covalent interaction occurs with the aromatic moiety of CRT006101’s phenolic 
ring. It has been documented that pi-pi stacking can assist in drug binding, which in drug 
discovery, is commonly found through T-shaped or parallel-displaced interactions61. 
 
 
  
 
Figure 21. Cellular PKD1 mutant resistance to CRT0066101 treatment 
 
HEK 293 cells transiently expressing Flag-PKD1-WT, Flag-PKD1-G664V, and Flag-
PKD1-G664I were serum starved for 18 hours. Following, cells were treated with the 
indicated concentration of CRT0066101 for 90 minutes and subsequently induced with 
10 nM of PMA. Cells were collected and lysed. Total cell lysate was analyzed by 
immunoblotting with anti-pSer916 PKD1-specific antibody for kinase activity, anti-flag 
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antibody for transfection efficiency, and anti-tubulin for loading control. Densitometric 
quantification was performed using Image Lab (Bio-Rad) and the activity was 
normalized against the transfection efficiency and with the loading control 
 
Next, we investigated pocket I exploitation by making amino acid substitutions at 
Gly664. Pocket I is hydrophobic in nature; however, it is solvent exposed and can tolerate both 
polar and non-polar functional groups. Therefore, we constructed G664V and G664I mutants, 
which have hydrophobic, aliphatic side chains that would be positioned within PKD’s active site. 
As previously described, we expressed Flag-PKD1-G664V and –G665I mutants in HEK 293 
cells in the presence of increasing concentrations of CRT0066101. Comparing the kinase activity 
to Flag-PKD1-WT, western blot analysis of PKD1’s activity according to PMA-induced PKD 
autophosphorylation at Ser916 indicated a decrease in CRT0066101 sensitivity (Figure 21). The 
cellular EC50 for Flag-PKD1-G664V and -G664I mutants was roughly 50 μM, which is an 
increase compared to Flag-PKD1-WT. This reduced sensitivity may suggest CRT0066101 
exploits, to some degree, pocket I. Although, it is unclear how these pocket I mutations 
specifically affect CRT0066101 binding. At higher concentrations CRT0066101 no longer 
perturbs mutant PKD activity. This may indicate a change in CRT0066101’s binding mode 
within PKD’s active site, altering its mechanism of inhibition; however, in-vitro evaluations 
using recombinant protein is required to provide further insight.    
The binding of PKD small molecule inhibitors within PKD’s kinase domain is poorly 
understood. This investigation provided new insight into the positioning of CRT0066101 and 
described regions of exploitation within PKD’s active site. In addition to improving our 
structural understanding of PKD inhibition, we indirectly developed a chemical genetic tool kit 
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to explore PKD within a biological system. Mutating the gatekeeper residue, Met659, to 
phenylalanine or tyrosine dramatically sensitized PKD to CRT0066101 inhibition. Conversely, 
mutating hinge residue, G664, to larger, more sterically cumbersome amino acids like valine or 
isoleucine conferred resistance. Therefore, these tools can be employed as a common strategy 
when evaluating PKD function using CRT0066101 pharmacological inhibition.  
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4.0  CONCLUSION AND FUTURE DIRECTION 
The pursuit to abrogate PKD catalytic function has led to the discovery of a series of 
effective PKD small molecule inhibitors. However, these inhibitory scaffolds have not 
transitioned to the clinic and therefore, further drug discovery efforts are necessary to establish a 
potential drug candidate. The work presented in this document has provided insightful analysis 
of type I ATP-competitive PKD inhibitors and proposes putative binding modes that describe 
important chemical characteristics essential for PKD inhibition. Thus, future initiatives should 
employ rational drug design and incorporate the appropriate functionality necessary for enhanced 
potency and selectivity. We believe this improved structural understanding will facilitate in 
efficient development of PKD small molecule inhibitors, thereby, providing greater opportunity 
for the discovery of a novel PKD therapeutic agent.  
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APPENDIX A 
MOLECULE MODELING  
 
 
Figure 22. PKD kinase homology model validation 
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A.  
 
 
Figure 23. Structural investigation into 4-Azaindole kinase inhibitor 
A. Chemical structure of 4-Azaindole, 9. B. 4-Azaindole, 9, bound to p38 MAP kinase 
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